Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live, attenuated, recombinant human respiratory syncytial virus expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing by more than 200-fold the peak shedding of SARS-CoV-2 in the nose. MV-014-212 elicited mucosal immunoglobulin A in the nose and neutralizing antibodies in serum that exhibited cross-neutralization against virus variants of concern Alpha, Beta, and Delta. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase 1 clinical trials as an intranasal COVID-19 vaccine.
【초록키워드】 COVID-19, neutralizing antibody, SARS-CoV-2, coronavirus, COVID-19 vaccine, clinical trial, Delta, global pandemic, Surface glycoprotein, serum, respiratory syncytial virus, cross-neutralization, Beta, RNA virus, immunoglobulin A, African green monkey, intranasal, SARS-CoV-2 spike, mucosal, administration, Live attenuated vaccine, chimeric, host cells, Phase 1, viral envelope protein, acute respiratory syndrome, immunogenic, AGMs, trimeric, exhibited, reducing, expressing, elicited, AGM, virus variant, 【제목키워드】 SARS-CoV-2, administration, recombinant COVID-19 vaccine, PROTECT,